Antibody that binds specifically to the sars cov 2 spike protein, and methods for its manufacture
AssigneeIgnova GmbH
InventorsJan WESJOHANN, Michael GERRITS, Tonchy UGRINOVIC, Nguyen VAN SA, Andreas MICHELS
Life of this patent
Estimating the term…
Abstract
The present invention relates to an antibody that binds specifically to the SARS CoV-2 spike protein, and methods for its manufacture.
Claims41
A method for isolating or producing antibodies, the method comprising:
- immunizing a female vertebrate animal by administration of at least one protein or peptide comprising at least one amino acid sequence selected from the group consisting of any one of SEQ ID NO:
- 1-SEQ ID NO:
- 15, SEQ ID NO:
- 17, SEQ ID NO:
- 19, SEQ ID NO:
- 21, SEQ ID NO:
- 23, SEQ ID NO:
- 25 or any one of SEQ ID NO:
- 26-SEQ ID NO:
- 41,
- collecting one or more lactation or ovulation product from the animal after immunization, and
- isolating or purifying at least one antibody from the products,
- wherein the protein or peptide is, comprises, or is a fragment of, the SARS CoV 2 spike protein
The method according to any one of the aforementioned claims, wherein the animal is a chicken.
The method according to any one of the aforementioned claims, wherein the ovulation product that is collected from the animal is one or more eggs.
The method according to any one of the aforementioned claims, wherein the antibody that is purified from the eggs is IgY.
The method according to any one of the aforementioned claims, wherein the animal is a female mammal.
The method according to any one of the aforementioned claims, wherein the animal is a ruminant.
The method according to any one of the aforementioned claims, wherein the animal is a cow, pig, camel, horse, donkey, goat or sheep.
The method according to any one of the aforementioned claims, wherein the lactation product collected from the animal is, whey, milk or colostrum.
The method according to any one of the aforementioned claims, wherein the antibody is at least one of IgA, IgG, and IgM.
The method according to any one of the aforementioned claims, wherein the protein or peptide comprising at least one amino acid sequence selected from the group consisting of any one of any one of SEQ ID NO:
- 1-SEQ ID NO:
- 15, SEQ ID NO:
- 17, SEQ ID NO:
- 19, SEQ ID NO:
- 21, SEQ ID NO:
- 23, SEQ ID NO:
- 25 or any one of SEQ ID NO:
- 26-SEQ ID NO:
- 41 has a maximum length as set forth in table 1.
The method according to any one of the aforementioned claims, wherein two or more proteins or peptides comprising at least one amino acid sequence selected from the group consisting of any one of any one of SEQ ID NO:
- 1-SEQ ID NO:
- 15, SEQ ID NO:
- 17, SEQ ID NO:
- 19, SEQ ID NO:
- 21, SEQ ID NO:
- 23, SEQ ID NO:
- 25 or any one of SEQ ID NO:
- 26-SEQ ID NO:
- 41 are used for immunizing the animal.
The method according to any one of the aforementioned claims, wherein
- a) at least one single chain protein or peptide is used for immunizing which comprises two or more subsequences each comprising an amino acid sequence selected from the group consisting of any one of any one of SEQ ID NO:
- 1-SEQ ID NO:
- 15, SEQ ID NO:
- 17, SEQ ID NO:
- 19, SEQ ID NO:
- 21, SEQ ID NO:
- 23, SEQ ID NO:
- 25 or any one of SEQ ID NO:
- 26-SEQ ID NO:
- 41, and/or
- b) at least one homo- or heterodimer, -oligomer or -multimer is used for immunizing which comprises two or more chains each comprising an amino acid sequence selected from the group consisting of any one of SEQ ID NO:
- 1-SEQ ID NO:
- 15, SEQ ID NO:
- 17, SEQ ID NO:
- 19, SEQ ID NO:
- 21, SEQ ID NO:
- 23, SEQ ID NO:
- 25 or any one of SEQ ID NO:
- 26-SEQ ID NO 29.
The method according to any one of the aforementioned claims, wherein at least one protein or peptide used for immunizing is conjugated to a second molecule known to be immunogenic in the animal being immunized.
The method according to any one of the aforementioned claims, wherein for immunization, an adjuvant is co-administered with the at least one protein or peptide.
The method according to any one of the aforementioned claims, wherein immunization is repeated between one and 10 times.
The method according to any one of the aforementioned claims, wherein, in the repeated immunization, the amount of the protein or peptide is reduced to between ≥70% and ≤10% of the initial dosis.
The method according to any one of the aforementioned claims, wherein immunization is performed by in at least two steps, wherein,
- c) in a first step, the bird or mammal is immunized by administration of at least one single chain protein or peptide which comprises two or more subsequences each comprising an amino acid sequence selected from the group consisting of any one of SEQ ID NO:
- 1-SEQ ID NO:
- 15, SEQ ID NO:
- 17, SEQ ID NO:
- 19, SEQ ID NO:
- 21, SEQ ID NO:
- 23, SEQ ID NO:
- 25 or any one of SEQ ID NO:
- 26-SEQ ID NO:
- 41, and
- d) in a second step performed after the first step the bird or mammal is immunized by administration of at least one monomer which comprises an amino acid sequence selected from the group consisting of any one of SEQ ID NO:
- 1-SEQ ID NO:
- 15, SEQ ID NO:
- 17, SEQ ID NO:
- 19, SEQ ID NO:
- 21, SEQ ID NO:
- 23, SEQ ID NO:
- 25 or any one of SEQ ID NO:
- 26-SEQ ID NO 29.
The method according to any one of the aforementioned claims, wherein at least one of the proteins or peptides used for immunization is produced by at least one of peptide synthesis or recombinant expression.
An antibody that binds specifically to a protein or peptide comprising a sequence selected from the group consisting of any one of any one of SEQ ID NO:
- 1-SEQ ID NO:
- 15, SEQ ID NO:
- 17, SEQ ID NO:
- 19, SEQ ID NO:
- 21, SEQ ID NO:
- 23, SEQ ID NO:
- 25 or any one of SEQ ID NO:
- 26-SEQ ID NO:
- 41, wherein the protein or peptide is, comprises or is a fragment of the SARS CoV-2 spike protein.
A combination of two or more antibodies that bind specifically to one or more proteins or peptides selected from the group consisting of any one of any one of SEQ ID NO:
- 1-SEQ ID NO:
- 15, SEQ ID NO:
- 17, SEQ ID NO:
- 19, SEQ ID NO:
- 21, SEQ ID NO:
- 23, SEQ ID NO:
- 25 or any one of SEQ ID NO:
- 26-SEQ ID NO:
- 41, wherein the proteins or peptides are, comprise or are a fragment of the SARS CoV-2 spike protein.
The antibody or antibodies or product according to any one of the aforementioned claims, the antibody or antibodies being co-administered with, or the product further comprising, at least one of
- a protease inhibitor, preferably an inhibitor of TMPRSS2 or an inhibitor of the CoV-2 C30 endopeptidase (also called Mpro or 3CLpro)
- a nucleoside or nucleotide analogue, preferably which is accepted by viral RNA-dependent RNA polymerase
- an IL-6 antagonist,
- a soluble angiotensin-converting enzyme 2, and/or
- a peptide that comprises a sequence that is homologous to the S1/S2 sequence of the SarsCov2 spike protein,
- wherein co-administration can be carried out concomitantly or consecutively.
Dependencies are inferred from the claim text.